In addition, by broad targeted sequencing of normal blood, germline variants with neoplastic pathogenicity were detected in genes known to be tumor agnostic biomarkers predicting response to immunotherapy (MLH1 and MSH2), or to PARP-inhibitors (BRCA2 and ATM). The gene discussed is BRCA2; the disease is neoplasm.